Article Information
PubMed
Published By
History
- Received May 30, 2008
- Revision received September 8, 2008
- Accepted September 29, 2008
- First published November 12, 2008.
- Version of record published November 12, 2008.
Copyright & Usage
Copyright © 2008 Society for Neuroscience 0270-6474/08/2812023-09$15.00/0
Author Information
- Sajjad Muhammad1,*,
- Waleed Barakat1,*,
- Stoyan Stoyanov2,
- Sasidhar Murikinati1,
- Huan Yang4,
- Kevin J. Tracey4,
- Martin Bendszus3,
- Grazisa Rossetti5,
- Peter P. Nawroth2,
- Angelika Bierhaus2, and
- Markus Schwaninger1
- 1Pharmacological Institute, and
- Departments of 2Internal Medicine and
- 3Neuroradiology, University of Heidelberg, 69120 Heidelberg, Germany,
- 4Feinstein Institute for Medical Research, Manhasset, New York 11030, and
- 5HMGBiotech, 20133 Milan, Italy
- Correspondence should be addressed to Dr. Markus Schwaninger, Pharmacological Institute, University of Heidelberg, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany. markus.schwaninger{at}pharma.uni-heidelberg.de
Author contributions
-
↵*S.M. and W.B. contributed equally to this work.
Disclosures
- Received May 30, 2008.
- Revision received September 8, 2008.
- Accepted September 29, 2008.
-
This work was supported by a grant from the Landesstiftung (Network Aging Research) Baden-Württemberg to A.B. and M.S., the Deutsche Forschungsgemeinschaft (SFB 405), and the Hopp Stiftung to P.P.N. K.J.T. is consultant to Critical Therapeutics, which has sponsored research and license agreements with The Feinstein Institute for Medical Research for patents related to inhibiting HMGB1. Grazisa Rossetti is employed by HMGBiotech, a company providing HMGB1-related reagents.
-
The authors declare competing financial interests.
- Correspondence should be addressed to Dr. Markus Schwaninger, Pharmacological Institute, University of Heidelberg, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany. markus.schwaninger{at}pharma.uni-heidelberg.de
Online Impact